Novel Rx
Dr. Rachel Tate uptoTate
4 years 10 months ago
Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
SKIPPAIN Trial: Dr. Sheila Reyes
Dr. Sheila Reyes reviews abstract #0899 presented at the 2020 ACR annual meeting.
Dr. Rachel Tate uptoTate
4 years 10 months ago
5yr DESIR cohort data estimated incidence rate of uveitis at 1.3/100p-y; over five years, uveitis was associated w/ dactylitis, biologic and sacroiliac MRI inflammation. #ABS1304 #ACR20 @RheumNow https://t.co/qmXlY7PmBB
alexa meara lexmeara
4 years 10 months ago
Important thoughts- how do we actually use the biologics in practice for the rare diseases that do not have many FDA approved options? @RheumNow #ACR20 abstract 1429 https://t.co/SsYC1kF5uv
Improving Response to Pegloticase: Dr. Nicola Dalbeth
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952.
Nomenclature, Uveitis and Other Spondyloarthritis Features: Dr. Lianne Gensler
Dr. Gensler reviews her top selections for ACR 2020 today, including abstract #0881 and #0876. She also highlighted the study group on spondyloarthritis, which focused on nomenclature.
Peter Nash drpnash
4 years 10 months ago
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study https://t.co/Z91MhXJ5HK #gca #tocilizumab #pet what about the radiation?
Peter Nash drpnash
4 years 10 months ago
The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series https://t.co/2OBy0lxd6b #hepb #tocilizumab #tofacitinib no reactivation in resolved infection
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 10 months ago
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 10 months ago
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Combo Therapy v Monotherapy (SEAM-RA Trial): Dr. Richard Conway
Dr. Conway discusses ACR abstract #0939 presented Saturday at the 2020 ACR annual meeting.
Treatment of Dermatomyositis Studies: Dr Robert Chao
Dr. Robert Chao reviews two important abstracts - #0955 (IVIg) and #0958 (tocilizumab) - on the treatment of dermatomyositis as presented at the 2020 ACR annual meeting.
Richard Conway RichardPAConway
4 years 10 months ago
Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W
What is the SEAMless transition from combination Etanercept to Methotrexate? Dr. Jonathan Kay
Dr. Jonathan Kay takes a deep dive into plenary abstract #0939 presented at the ACR 2020 annual meeting, reviewing two previous clinical trials that also looked at this question and offering his perspective.
Poster Hall